ReviewFrontiers in oncology2014
Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.Cancer chemotherapy and pharmacology · 2016Trial
- Review
- GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system.NPJ precision oncology · 2025Review
- Unraveling the glycosphingolipid metabolism by leveraging transcriptome-weighted network analysis on neuroblastic tumors.Cancer & metabolism · 2024Article
- Role of Immunotherapy in Sarcomas.International journal of molecular sciences · 2024Review
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.Frontiers in immunology · 2024Review
- Advances in new targets for immunotherapy of small cell lung cancer.Thoracic cancer · 2024Review
- A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood.Journal of clinical medicine · 2023Article
- Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.Nature cancer · 2022Article
- Review
- Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment.Cancers · 2021Review
- Serum Protein N-Glycosylation Signatures of Neuroblastoma.Frontiers in oncology · 2021Article
- Gangliosides and Neuroblastomas.International journal of molecular sciences · 2020Review
- Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.Cancer medicine · 2020Article
- Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.Frontiers in oncology · 2020Review
- Comprehensive Profiling of Surface Gangliosides Extracted from Various Cell Lines by LC-MS/MS.Cells · 2019Article
- Modulation of Endocannabinoid-Binding Receptors in Human Neuroblastoma Cells by Tunicamycin.Molecules (Basel, Switzerland) · 2019Article
- Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.Biologics : targets & therapy · 2019Review
- Cell death-based treatment of neuroblastoma.Cell death & disease · 2018Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma (NB), accounting for 10% of childhood cancers, exhibits aberrant cell-surface glycosylation patterns. There is evidence that changes in glycolipids and protein glycosylation pathways are associated to NB biological behavior. Polysialic acid (PSA) interferes with cellular adhesion, and correlates with NB progression and poor prognosis, as well as the expression of sialyltransferase STX, the key enzyme responsible for PSA synthesis. Galectin-1 and gangliosides, overexpressed and actively shedded by tumor cells, can modulate normal cells present in the tumor microenvironment, favoring angiogenesis and immunological escape. Different glycosyltransferases are emerging as tumor markers and potential molecular targets. Immunotherapy targeting disialoganglioside GD2 rises as an important treatment option. One anti-GD2 antibody (ch14.18), combined with IL-2 and GM-CSF, significantly improves survival for high-risk NB patients. This review summarizes our current knowledge on NB glycobiology, highlighting the molecular basis by which carbohydrates and protein-carbohydrate interactions impact on biological behavior and patient clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.